Riskpilot← Back to searchSign inGet full accessVixiMed AB
ABActiveOrg 5568033087Kungsgatan 62 3 TrResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20101 employees
Revenue 2024
SEK 1,9M
-10% vs 2023
EBITDA margin
-5.1%
-143% vs 2023
Equity ratio
58.4%
Financial strength
Net profit 2024
SEK -71K
-145% vs 2023
| Revenue | SEK 1,9M | -10% |
| EBITDA | SEK -95K | -143% |
| Net profit | SEK -71K | -145% |
| Total assets | SEK 1,1M | -10% |
| Equity | SEK 638K | -21% |
| Employees | 1 | — |
Legal name
VixiMed AB
Org number
5568033087
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
1 april 2010
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firmanbeträffande löpande förvaltningsåtgärder
Company purpose
Bolaget ska bedriva konsultverksamhet, utveckling och marknads- föring av medicintekniska system och därmed förenlig verksamhet.
Address
Kungsgatan 62 3 Tr
Phone
+46709965965
Email
info@viximed.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 2 694 | 2 377 | 1 869 | 2 084 | 1 875 |
| Staff expenses | — | — | — | −1 042 | −1 056 |
| EBITDA | 359 | — | −338 | 222 | −95 |
| Depreciation & amort. | −15 | −15 | −11 | −1 | — |
| EBIT | 344 | −15 | −349 | 221 | −95 |
| Net financials | −1 | — | — | 4 | 7 |
| Profit before tax | 256 | 37 | −315 | 225 | −88 |
| Tax | −73 | −37 | 39 | −66 | 17 |
| Net profit | 183 | 0 | −276 | 159 | −71 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 1 903 | 1 561 | 1 085 | 1 219 | 1 093 |
| Equity | 987 | 926 | 650 | 809 | 638 |
| Long-term debt | 0 | 0 | 0 | — | — |
| Short-term debt | 829 | 600 | 435 | 410 | 455 |
| Total debt | 829 | 600 | 435 | 410 | 455 |
EBITDA margin
-5.1%
This company
15.8%
Market median
-132% vs market
20202024
Equity ratio
58.4%
This company
38.2%
Market median
+53% vs market
20202024
Return on equity
-11.2%
This company
18.4%
Market median
-161% vs market
20202024
Net profit margin
-3.8%
This company
8.1%
Market median
-147% vs market
20202024
Asset turnover
1.72×
This company
1.12×
Market median
+54% vs market
20202024
Debt / equity
0.71×
This company
0.62×
Market median
+15% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
PE Chief Executive Officer | Chief Executive Officer | 2022 |
JE | Audit | 2022 |
| Former (1) | ||
KL Audit | Audit | 2022 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Board of Directors | 2022 | |
| Board of Directors | 2022 | |
| Chairman | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of VixiMed AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Per Emanuel Hillberg | Chief Executive Officer | 0 companies |
| Karl Leonard Daun | Audit | 0 companies |
| Johan Erik Niclas Bergenmo | Audit | 0 companies |
| Åke Mikael Marjamäki | Board of Directors | 0 companies |
| John Göran Thomas Sennmark Moberg | Board of Directors | 0 companies |
| Mats Christer Wallnér | Chairman | 0 companies |